Trials / Completed
CompletedNCT01010945
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- OSI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.
Detailed description
This is a single-arm, phase 1b study to determine the maximum tolerated dose (MTD) of the combination of erlotinib (daily), gemcitabine (weekly), nab-paclitaxel (weekly) in patients with advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib | administered orally |
| DRUG | gemcitabine | administered intravenously |
| DRUG | nab-paclitaxel | administered intravenously |
Timeline
- Start date
- 2010-02-03
- Primary completion
- 2012-01-25
- Completion
- 2012-01-25
- First posted
- 2009-11-10
- Last updated
- 2024-11-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01010945. Inclusion in this directory is not an endorsement.